Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will ...

Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr.

COVINGTON, Ky., Jan. 8, 2025 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel, first-in-class biologic therapy to treat solid tumors and ...

Guardant Health, Inc., a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant’ s precision ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 an ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and ...

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers Dec. 18, 2024 7:30 AM ET Agenus Inc. (AGEN) ...

In addition to obesity, modifiable risk factors include a low-quality diet (such as high consumption of processed meats, ...

MCCLEAN, VA, UNITED STATES, January 23, 2025 / EINPresswire.com / -- Perthera, a leader in precision oncology, will present follow-on research and validation of the world’s first AI-driven chemo ...

MCCLEAN, VA, UNITED STATES, January 23, 2025 / EINPresswire.com / -- Perthera, a leader in precision oncology, will present follow-on research and validation of the world’s first AI-driven chemo ...